

Program • Wednesday September 26

Coffe and sandwich will be served from 08.30	
09.00-10.00	Registration
OPENING SESSION Moderators: Magnus Gisslén & Nina Weis	
10.15-10.20	Welcome (Nina Weis, Denmark)
10.20-10.50	Opening Plenary 1 Progress towards reaching the 90-90-90 HIV target in Europe and beyond (Anastasia Pharris, ECDC, Sweden)
10.50-11.00	Discussion
ABSTRACT SESSION I (10 min + 5 min discussion) Moderators: Magnus Gisslén & Nina Weis	
11.00-11.15	Oral 1 - HPV genotypes identified in migrant women living with HIV are not covered for by current HPV vaccines; results from an interim analysis Christina Carlander
11.15-11.30	Oral 2 - Frequency of co-expression of inhibitory receptors early in HIV infection determines progression rate in untreated patients. Lydia Scharf
11.30-11.45	Oral 3 - Switching to FTC/TAF from either ABC/3TC or FTC/TDF does not affect central nervous system HIV-1 infection Aylin Yilmaz
11.45-12.00	Oral 4 - Gut mucosal CD4 T cells of immunological non-responders with low CD4/CD8 ratio have increased cytokine production, which may be reduced by probiotics Malin H Meyer-Myklestad
12.00-13.00	Lunch
PLENARY SESSION I - Moderators: Matti Ristola & Magnus Gottfredsson	
13.00-13.30	Plenary 2 Mortality and morbidity among children and adolescents with perinatal HIV infection (Ruth Goodall, UK)
13.30-13.40	Discussion
13.40-14.10	Plenary 3 HIV infected women and breastfeeding (Ellen Moseholm Larsen, Denmark)
14.10-14.20	Discussion
14.20-14.35	Short break
14.35-15.50	BHIVA and HIV Nordic joint session- Aspects on HIV prevention in high-risk-populations Moderators: Magnus Gisslén & Caroline Sabin Chemsex (Ann Sullivan, UK). PrEP, implementation in Norway (Frank Olav Pettersen, Norway). Declining HIV prevalence among MSM in London(Ann Sullivan, UK)
15.50-16.30	Coffee and exhibition/posters
16.30-17.30	Satellite Symposium I (Janssen) What you need to know about HIV and bone – a medical education event Moderator: Lars Østergaard, Skejby, Aarhus, Denmark Speakers: Mas Chaponda, Royal Liverpool University Hospital, Liverpool, UK, Steffen Leth, Skejby, Aarhus, Denmark, Jon Wetterberg, Venhälsan, Södersjukhuset i Stockholm
17.30-17.45	Short break
17.45-18.45	Satellite Symposium II (GSK/ViiV) Can less be more? Let 2-morrow start 2-day Moderator: Eva Fernvik, Sr Scientific Advisor HIV, GSK/ViiV Healthcare Why use a two drug regimen (2DR)? – Tia Vincent, PhD, Director Global Scientific Affairs, ViiV Healthcare The hiv-patient and stigma – the biggest hurdle for a life with high quality? – Maria Lindberg Reinius, RN, PhD, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet
18.45-	Poster Exhibition with cheese and snacks

Program • Thursday September 27

07.30-08.00	Breakfast is served outside the plenary hall on behalf of HIV Outcome
08.00-09.00	Satellite Symposium III HIV Outcome Stigma inom hälsovårdssystemet -behövs en certifiering? <i>(The lecture and discussion will be in Swedish)</i> Speakers: Anders Sönnnerborg, Karolinska Institutet. Lars E. Eriksson, Karolinska Institutet, Peter Månehall, HIV-Sverige & a group of panelist for a concluding discussion
09.00-09.10	Short break
	PLENARY SESSION II - Inflammation and reservoirs Moderators: Anders Sönnnerborg & Annika Karlsson
09.10-09.40	Plenary 6 Tissue resident T-cells and immunity during acute and chronic HIV-infection (Michael Betts, USA)
09.40-09.50	Discussion
09.50-10.20	Plenary 7 Microbial translocation and microbiome dysbiosis in HIV-associated immune activation (Piotr Nowak, Sweden)
10.20-10.30	Discussion
10.30-11.00	Coffee and exhibition/posters
11.00-11.30	Plenary 8 Is it possible to enhance immune function in HIV-infected persons on ART with immune failure? (Michael Lederman, USA)
11.30-11.40	Discussion
	PLENARY SESSION III - Living with HIV Moderators: DH Reikvam & Aylin Yilmaz
11.40-12.10	Plenary 9 Life expectancy and long-term outlook in PLHIV (Caroline Sabin, UK)
12.10-12.20	Discussion
12.20-12.50	Plenary 10 Recent achievements in Next-Generation Sequencing (NGS) of HIV and possible clinical implications (Roger Paredes, Spain)
12.50-13.00	Discussion
13.00-14.00	Lunch
	PLENARY SESSION IV-Last year's most important achievements in the HIV reserach field. Moderators: Francesca Chiodi & Jan Gerstoft
14.00-14.30	Plenary 11 Top 5 in basic HIV research 2017-2018 (Jan Albert, Sweden)
14.30-14.40	Discussion
14.40-15.10	Plenary 12 Top 5 in clinical HIV research 2017-2018 (Anne-Mette Lebech, Denmark)

Program • Thursday September 27

15.10-15.20	Discussion
15.20-15.40	Plenary 13 The history of HIV in Finland (Matti Ristola, Finland)
15.40-15.45	HIV & Hepatitis Nordic Conference 2018 Abstract Award (Matti Ristola, Finland)
15.45-16.15	Coffee and exhibition/posters
16.15-17.15	Satellite Symposium IV (Gilead HIV) What is the role of the new integrase inhibitor in the management of HIV patients? Moderator: Leo Flamholz, Department of infectious diseases, Malmö University hospital Lecturer: Sr. Director of Medical Affairs, Gilead Sciences Inc, USA
	Conference dinner

Program • Friday September 28

07.30-08.00	Breakfast is served outside the plenary hall on behalf of Gilead HCV
08.00-09.00	<p>Satellite Symposium V (Gilead HCV) Elimination of HCV-experience from Iceland</p> <p>Moderator: Soo Aleman MD, PhD, assoc prof. head of HIV, viral hepatitis and immunodeficiency units at Department of Infectious Diseases, Karolinska University Hospital</p> <p>Lectures: Valgerður Rúnarsdóttir, Medical Director, Vogur University Hospital Sigurdur Olafsson, Director of Hepatology, Landspítali University Hospital Magnus Gottfredsson, MD, PhD, Landspítali University Hospital</p>
	<p>PLENARY SESSION V- Last years's most important achievements in the hepatitis field Moderators: Ola Weiland & Helene Mens</p>
09.10-09.40	Plenary 14 Top 5 in hepatitis research 2017/18 (Martti Färkkilä, Finland)
9.40-09.50	Discussion
	<p>ABSTRACT SESSION II (10+5 min discussion) Moderators: Ola Weiland & Helene Mens</p>
09.50-10.05	Oral 5- Acute Hepatitis E Virus Genotype 3 Infection Associated with Acute Pancreatitis Miriam Karlsson
10.05-10.20	Oral 6- Enhancing the hepatitis C (HCV) care cascade for people who inject drugs (pwid) at the Stockholm needle exchange Martin Käberg
10.20-11.00	Coffee and exhibition/posters
	<p>PLENARY SESSION VI Moderators: Magnus Lindh & Nina Weis</p>
11.00-11.30	Plenary 15 Update on hepatitis E (Heléne Norder, Sweden)
11.30-11.40	Discussion
11.40-12.10	Plenary 16 Can HCC surveillance be stopped?/ Post SVR surveillance (Sofie Hallager, Denmark)
12.10-12.20	Discussion
12.20-13.20	Lunch
	<p>PLANERY SESSION VII Moderators: Leo Flamholc & Ola Weiland</p>
13.20-13.50	Plenary 17 HCV treatment in needle exchange programs (Marianne Alanko, Sweden)
13.50-14.00	Discussion
14.00-14.30	Plenary 18 HCV treatment in prison systems (Soo Aleman, Sweden)
14.30-14.40	Discussion
15.20-15.40	Plenary 19 Global Perspectives on HCV Eradication (Jeffrey V. Lazarus, UK)
15.40-	Discussion
15.20-15.30	Concluding remarks Moderator: Magnus Gisslén